Table 2.
Sample size | Groups | Comparisons between group | |||
---|---|---|---|---|---|
129 | 129 | p-Value | q-Value | ||
Type of hyaluronan injections | Chemically cross-linked | Avian derived | |||
VAS | CCH | ADH | |||
BL | 58.82±1.4 | 58.58±1.49 | 0.876 | N/A | |
30 days | Pain score | 24.22±1.43 | 35.47±2.87 | <0.0001 | 46.216 |
p-Value | <0.0001 | <0.0001 | |||
q-Value | 170.35 | 89.051 | |||
90 days | Pain score | 23.45±1.67 | 35.02±1.89 | <0.0001 | 56.178 |
p-Value | <0.0001 | <0.0001 | |||
q-Value | 174.17 | 90.733 | |||
180 days | Pain score | 21.6±2.14 | 34.33±1.96 | <0.0001 | 54.803 |
p-Value | <0.0001 | <0.0001 | |||
q-Value | 183.29 | 93.39 |
VAS – visual analog scale; BL – baseline. Data were represented as mean ±SD. Wilcoxon test (within the group) or independent t-test (between group) following Bonferroni adjustment was used for statistical analysis. A p<0.05 and q>2.652 were considered as significant. Within-group p-value was respect to BL. A 0: No pain and 100: Worst possible pain. N/A – not applicable.